NORTHERN TRUST CORP - ARCUTIS BIOTHERAPEUTICS INC ownership

ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 136 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 4.21 and the average weighting 0.1%.

Quarter-by-quarter ownership
NORTHERN TRUST CORP ownership history of ARCUTIS BIOTHERAPEUTICS INC
ValueSharesWeighting
Q3 2023$2,567,380
-42.1%
483,499
+3.8%
0.00%
-100.0%
Q2 2023$4,437,673
+4.3%
465,653
+20.4%
0.00%0.0%
Q1 2023$4,255,471
-25.3%
386,861
+0.5%
0.00%0.0%
Q4 2022$5,695,810
-20.2%
384,852
+3.0%
0.00%
-50.0%
Q3 2022$7,141,000
+6.4%
373,701
+18.6%
0.00%
+100.0%
Q2 2022$6,714,000
+34.6%
315,058
+21.7%
0.00%0.0%
Q1 2022$4,987,000
-10.9%
258,937
-4.1%
0.00%0.0%
Q4 2021$5,599,000
-13.4%
269,953
-0.2%
0.00%0.0%
Q3 2021$6,463,000
-18.4%
270,519
-6.8%
0.00%0.0%
Q2 2021$7,916,000
+2.6%
290,103
+8.7%
0.00%0.0%
Q1 2021$7,719,000
+14.2%
266,818
+11.1%
0.00%0.0%
Q4 2020$6,758,000
+9.7%
240,255
+14.3%
0.00%0.0%
Q3 2020$6,162,000
+58.8%
210,268
+63.8%
0.00%0.0%
Q2 2020$3,881,000
+20.1%
128,330
+18.3%
0.00%0.0%
Q1 2020$3,232,000108,4590.00%
Other shareholders
ARCUTIS BIOTHERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Frazier Life Sciences Management, L.P. 8,684,232$165,956,00012.78%
Bain Capital Life Sciences Investors, LLC 3,000,000$57,330,0006.84%
Pivotal bioVenture Partners Investment Advisor LLC 569,041$10,874,0003.97%
Logos Global Management LP 1,525,000$29,143,0003.58%
1492 Capital Management LLC 178,320$3,408,0002.45%
Cormorant Asset Management, LP 1,000,000$19,110,0001.34%
MPM BioImpact LLC 257,185$4,915,0001.16%
Orbimed Advisors 2,800,000$53,508,0000.99%
SECTORAL ASSET MANAGEMENT INC 220,985$4,223,0000.83%
Rubric Capital Management LP 472,047$9,021,0000.45%
View complete list of ARCUTIS BIOTHERAPEUTICS INC shareholders